UNITED
STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR
15(d)
OF THE SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event
reported): December 27,
2022
AMPIO PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
001-35182
|
26-0179592
|
|
(State or other jurisdiction
of
incorporation)
|
(Commission File Number)
|
(IRS Employer Identification
No.)
|
373 Inverness Parkway, Suite
200
Englewood, Colorado
80112
(Address of Principal Executive
Offices) (Zip Code)
Registrant’s telephone number,
including area code: (720)
437-6500
Not Applicable
(Former name, or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
☐Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
☐Pre-commencement communications pursuant to
Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
Common Stock, $0.0001 par
value
|
AMPE
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ☐